CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients

Yanwei Zhang,Beibei Sun,Minjuan Hu,Yuqing Lou,Jun Lu,Xueyan Zhang,Huimin Wang,Jialin Qian,Tianqing Chu,Baohui Han
DOI: https://doi.org/10.3389/fonc.2020.01049
IF: 4.7
2020-01-01
Frontiers in Oncology
Abstract:Background:This study was performed to evaluate the value of inflammatory biomarkers in predicting the prognosis of early-stage (stage IA-IIB) lung adenocarcinoma. Methods:Ten inflammatory biomarkers were tested with a Luminex bead-based assay in early-stage lung adenocarcinoma patients who underwent resection. Results:A total of 152 early-stage lung adenocarcinoma patients were analyzed in this study. The mean patient age (SD) was 59.9 (9.4) years. In total, 58.6% of patients were females, and never smokers accounted for 84.0%. Lung adenocarcinoma patients with high CXCL9 levels had a 71% reduced risk of recurrence relative to patients with low CXCL9 levels (HR= 0.29, 95% CI: 0.13-0.64,p= 0.0021). After Bonferroni correction, CXCL9 remained significantly related to the risk of early-stage lung adenocarcinoma recurrence. Lung adenocarcinoma patients with high CXCL9 levels had an 80% reduced risk of death relative to patients with low CXCL9 levels (HR= 0.20, 95% CI: 0.05-0.78,p= 0.021), and those in the TCGA validation cohort were at a 29% reduced risk of death (HR= 0.71, 95% CI: 0.45-0.99,p= 0.044). Conclusion:Our results demonstrate for the first time that the CXCL9 level is a protective factor for both disease-free survival (DFS) and overall survival (OS) in early-stage lung adenocarcinoma patients.
What problem does this paper attempt to address?